Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
February 8, 2021

Coronavirus company news summary – SureScreen Diagnostics to supply 20 million rapid lateral flow tests to the UK – USC AI tool can predcoronavirus mutations

By Chloe Kent

Derby-based test manufacturer SureScreen Diagnostics will supply 20 million validated Covid-19 lateral flow antigen tests to the UK government. The tests will help meet the government’s efforts to deliver rapid testing asymptomatic individuals, to break transmission chains. The tests produce results in less than 30 minutes and are the first British tests to be validated in the Public Health England (PHE) laboratory.

University of California (USC) researchers have launched a new artificial intelligence (AI) tool to counter Covid-19 mutations and hasten vaccine development. The research team has developed a machine-learning model to speed up vaccine analysis that once took months or years, and now takes only minutes or seconds to find the best preventive medical therapy.

Ottawa researchers have discovered a test that can identify Covid-19 variants in wastewater. This was based on the recently detected variant in a sample of wastewater from Barrie, Ontario. Canadian researchers have already been testing wastewater for the SARS-CoV-2 virus. Research indicates that infected individuals can shed the virus through their faeces.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU